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NATURAL xenophile antibodies (NXA) and induced xenophile antibodies (XA) are considered a major 
barrier to organ transplantation between phylogeneticaliy 
discordant species and are held to be responsible for 
hyperacute and acute rejection of xenogeneic organs.! The 
aims of this study were (1) to analyze the kinetics of NXA 
and XA in the xenogeneic model "rat antihuman," which 
allows experimental manipulation, and (2) to manipulate 
NXA and XA production by the new immunomodulating 
drug leftunomide (LF). LF is thought to preferentially 
inhibit T-dependent B-Iymphocyte proliferation by antag-
onizing a T-helper cell-derived soluble, B-cell activating 
factor, possibly an interleukin.2 
MATERIALS AND METHODS 
Animals and Xenogeneic Sensitization 
Two- to three-month-old male LEW rats received 2 x 107 human 
peripheral blood lymphocytes (PBL) in 2 mL RPMI-I640 (lP) on 
day O. 
LF Treatment 
A 77 1726, the water-soluble metabolite of LF (Hoechst Company, 
Kalle-Albert, Wiesbaden, Germany), was applied daily IP from 
day 0 to day + 10 at either 3 or 10 mg/kg/d. LF was tolerated well 
by all individuals, even in the relatively high dose of IO mg/kg. 
Sampling of Test Sera 
LEW sera were prepared from tail vein blood at regular intervals 
posttreatment, stored at -80°C, and heat inactivated before use to 
eliminate complement function. 
Analysis of NXA and XA 
Rat sera were titrated and added to vital human PBL for 45 
rnin/20°C. After extensive washings, fluorescein isothiocyanate 
(FITC)-conjugated goat antirat IgG or IgM were added to PBL as 
secondary antibodies. NXA and XA binding was quantitated by 
flow cytornetry using a FACScan (Becton Dickinson). 
RESULTS 
NXA in Nonsensitized Rats 
Male LEW rats have NXA in their sera that bind to viable 
human PBL, mostly with a median IgM titer of 1:4 and a 
median IgG titer of < 1 : I. This observation refers to 31 of 
40 normal rat sera, where binding of IgM was markedly 
stronger than binding of IgG, as expected. In 7 of 40 sera, 
however, binding of IgM was equal for binding of IgG and 
in 2 of 40 sera it was weaker. 
LF Treatment of Nonsensitized Rats 
Nonsensitized rats that receive \0 mg/kg/d LF for \0 days 
(n = 8) show a decrease of NXA binding on day + 11 
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(about 30% reduction of IgG; about 50% reduction 
IgM). NXA titers rise again when LF treatment is termi-
nated, however: (I) above normal (presumably as a re-
bound effect) up to day +40 and (2) back to normal beyond' 
day +40. 
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Fig 1. Dose-dependent inhibition of xenogeneic sensitization (rat 
antihuman PBL model) by LF. Male LEW rats were sensitized on 
day 0 with 2 x 107 human PBL IP and received either 3 mg/kg or 
10 mg/kg LF IP from day 0 to day + 1 O. IgG (a) and IgM (b) titers 
of XA in sera of sensitized and LF-treated rats were measured by 
flow cytometry either immediately on day + 1 0, or 20 days after the 
end of LF treatment on day +30; n = 5 per experiment. 
From the Institute of Immunology, Medical School, University of 
Kiel (K.U., J.K., W.M.-R.), and Hoechst Immunopharmacology 
(R.B.), Kalle-Albert, Wiesbaden, Germany. 
Supported by grant UL 67/1-1 from the Deutsche Forschungs-
gemeinschaft. Germany. 
Address reprint requests to Or K. Ulrichs, Institute of Immunol-
ogy, Medical School of the University, Brunswikerstr. 4, D-2300 
Kiel, Germany. 
© 1992 by Appleton & Lange 
0041-1345/92/$3.001 + 0 
Transplantation Proceedings, Vol 24, No 2 (April), 1992: pp 718-719 
LF: IMMUNOMODULATING DRUG 
XA in Sensitived Rats 
A single JP injection of xenogeneic human PBL antigen on 
day 0 changes the XA reactivity pattern in untreated LEW 
sera. Expectedly, XA production strongly increases and 
switches from IgM to IgG (IgG titers range from I: 1024 to 
I: 16384; (gM titers range from 1:4 to 1:256). IgG titers 
remain stable over the observation period (up to day + 50), 
while IgM titers continuously decrease after day + 10. 
LF Treatment of Sensitized Rats 
Treatment of xenogeneically sensitized LEW rats with 3 or 
10 mg/kg LF from day -4 to day + 10 inhibits both (gG and 
JgM XA production in a dose-dependent manner (Fig I). 
This significant suppression of B-Iymphocyte activation is 
maintained only during the period of LF application. 
Twenty days after LF has been withdrawn, IgG and IgM 
titers increase and resemble the untreated sensitized con-
trols. 
DISCUSSION 
The isoxazol derivative LF, a novel immunosuppressant, 
is thought to antagonize cytokine activity and thus to 
interfere with T-helper cell-dependent B- and T-Iympho-
cyte prolifcration.2 Its inhibitory effects on various exper-
imental autoimmune diseases originally marked LF a 
strong inhibitor of B-cell activation. 3 This effect led us to 
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study the potential of LF to suppress NXA- and XA-
specific B-cell activation. 
In spite of low serum titers, cytotoxic NXA are consid-
ered to be the main cause of hyperacute xenograft rejec-
tion in discordant combinations and are known to be very 
therapy resistant.4 It is evident from our studies that when 
LF is applied permanently it is capable of significantly 
inhibiting the renewed production of both IgM and IgG 
NXA in nonsensitized rats. More interestingly, the effi-
cacy of LF increases when rat B lymphocytes, which are 
specific for XA, are activated by human xenoantigen (Fig 
I). The activity of these cells is apparently suppressed for 
the duration of drug treatment. LF is also tolerated well. It 
therefore appears to be an attractive alternative to efforts 
that combine NXA- or XA-depleting procedures, for ex-
ample, plasmapheresis, with conventional cytotoxic drug 
therapy, for example, cyclophosphamide.5 
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